Image-only AI wound-care companies
Analyze photographs. See a wound at a moment in time. Have no visibility into what treatment is doing to it.
Why Both
Owning Both Halves Is the Only Way to Build the Dataset.
Every AI wound-care company on the market analyzes images. None of them own a therapy device. That gap is the opportunity.
Fusing imaging with actual therapy data — pressure levels, seal failures, stim dose, adherence — against healing outcomes requires owning both halves of the loop. No one else can build that dataset, because no one else has both halves.
Landscape
Why No Competitor Can Follow
Device-only NPWT companies
Deliver therapy. Log runtime, pressure, and alarms. Cannot quantify whether the wound is actually responding.
Marrian Medical Technologies
Owns both. Every image is paired with the pressure levels, seal integrity, stim dose, and adherence that produced it — labeled by the healing outcome that followed.
The Dataset
Four Signals. One Labeled Record.
Because both products are built by the same company, every therapy session generates a multi-signal record. Imaging is no longer interpreted in isolation — it is contextualized by the therapy that produced it and the outcome that followed.
Imaging
Serial wound photographs, edge-detection, tissue segmentation.
Therapy telemetry
Pressure levels, seal failures, stim dose, cycle history.
Adherence
Actual runtime vs. prescribed regimen.
Outcome
Time-to-closure, stalling, complication events.
Compounding Advantage
A Moat That Grows With Use
An image-only company can improve its model with more pictures. Marrian improves its model with more pictures and the therapy telemetry and outcomes tied to each one.
Every deployed therapy session enriches the intelligence layer. Every improvement to the intelligence layer sharpens how the therapy is delivered. The two halves compound.
Designed to accelerate wound closure; efficacy under preclinical investigation. No clearance obtained.
Discuss the Thesis
For qualified investors, research institutions, and strategic partners interested in the integrated platform approach.